ライフサイエンスコーパス: autologous T cell

1 eration and IFN-gamma and IL-17 responses of autologous T cells.

2 g of blood-derived dendritic cells (DCs) and autologous T cells.

3 nctional in stimulating the proliferation of autologous T cells.

4 ly reduced functional responses to activated autologous T cells.

5 e pulsing them with HIV and mixing them with autologous T cells.

6 subsequent MDDC maturation and activation of autologous T cells.

7 with JAK3 mutations despite the presence of autologous T cells.

8 e, with residual development and function of autologous T cells.

9 c dendritic cells (moDC) and co-culture with autologous T cells.

10 tin synapse formation in both allogeneic and autologous T cells.

11 gamma production by M. tuberculosis-specific autologous T cells.

12 e, using genetically redirected syngeneic or autologous T cells.

13 tetanus toxoid complexes and cocultured with autologous T cells.

14 n CD34(+) hematopoietic progenitor cells and autologous T cells.

15 on and IL-5, but not IFNgamma, production by autologous T cells.

16 ected with NTHi in vitro and cocultured with autologous T cells.

17 c cells compared with cotransplantation with autologous T cells.

18 imulate proliferation of both allogeneic and autologous T cells.

19 te proliferation and IFN-gamma production by autologous T cells.

20 cation of tumor antigens (TAs) recognized by autologous T cells.

21 anoma cells and used to stimulate peripheral autologous T cells.

22 sed to present a recombinant Sp17 protein to autologous T cells.

23 -stimulated DCs led to targeted expansion of autologous T cells against tumor-associated antigens, in

24 responsive cells suppressed proliferation of autologous T cells, an effect that was dependent on IL-1

25 The DCs were coincubated with autologous T cells and the cytolytic activity of the T c

26 ts were cocultured with resting or activated autologous T cells and their activation was assessed by

27 rbital decompression surgery were mixed with autologous T cells, and fibroblast proliferation was det

28 The EBV-LCL J1s were cocultured with autologous T cells, and the proliferative and cytotoxic

29 Significantly, the results show that autologous T cells are primed by the fusion cells to ind

30 d by ex vivo anti-CD3/anti-CD28 costimulated autologous T cells at day 2 after transplantation.

31 ns expressed CD25 and reacted with activated autologous T cells but not resting T cells, irrespective

32 To determine whether autologous T cells can drive proliferation of orbital fi

33 Four infusions of autologous T cell clones were administered, the first wi

34 utation in FOXP3, allowing the comparison of autologous T-cell clones that do or do not express FOXP3

35 ing MDRCs, which stimulated proliferation of autologous T cells, comprised a high fraction of MDRCs i

36 ulatory cells, since their addition to fresh autologous T cells cultured with autologous nontransduce

37 t intense immunosuppressive conditioning and autologous T-cell-depleted hematopoietic transplantation

38 ells, because similarly activated polyclonal autologous T cells did not have this effect.

39 Autologous T cells directed to the LMP2 or LMP1 and LMP2

40 Adoptive immunotherapy using autologous T cells endowed with chimeric antigen recepto

41 The adoptive transfer of autologous T cells engineered to express a chimeric anti

42 trial to evaluate the safety and activity of autologous T cells engineered to express an affinity-enh

43 ular chimera), engineered to express several autologous T cell epitopes and sequences derived from th

44 on of CD14(+)HLA-DR(lo/-) MDSC that suppress autologous T cells ex vivo in a STAT-3-dependent manner.

45 ss proliferation and IFN-gamma production by autologous T cells ex vivo.

46 g DC-stimulated autologous T cells than with autologous T cells expanded by culture with interleukin-

47 Autologous T cells expressing a CD19-specific chimeric a

48 vivo vaccine-primed and ex vivo costimulated autologous T cells followed by post-transplant booster i

49 ted EBNA-3A peptide, FLRGRAYGL, and added to autologous T cells for 7 days at a DC:T ratio of 1:5 to

50 yte-restricted antigen that is recognized by autologous T cells from a patient with melanoma.

51 d patient tumor and lymphocytes showing that autologous T cells from cancer patients can be engineere

52 ellular antigens by dendritic cells (DCs) to autologous T cells from healthy donors.

53 D40 ligand, leading to strong stimulation of autologous T cells from HIV-1-infected individuals, but

54 that these cells can drive a Th1 response in autologous T cells from sensitized individuals.

55 ffect on the activation and proliferation of autologous T cells from the peritoneal cavity of patient

56 using a Theileria-transformed cell line and autologous T cells from Theileria-infected cattle.

57 preparative chemotherapy regimen followed by autologous T cells genetically engineered to express a c

58 ma or mantle cell lymphoma were treated with autologous T cells genetically modified by electroporati

59 with relapsed B-cell lymphomas treated with autologous T cells genetically modified to express a CD2

60 emia (NHL/CLL) or multiple myeloma (MM) with autologous T cells genetically modified to express kappa

61 s expressed by tumor cells and recognized by autologous T cells has led to the prospect of treating c

62 Therapy with genetically modified autologous T cells has shown great promise in cancer the

63 ell as melanoma cells for which responses by autologous T cells have been detected.

64 cted patients are infected and cultured with autologous T cells, IL-10 was produced in 6 of 10 patien

65 ith advanced stage melanoma, which inhibited autologous T cells in a manner relying up prostaglandin

66 In contrast, CWRBA-transduced DCs primed autologous T cells in an antigen-specific, MHC-restricte

67 rthritis elicit spontaneous proliferation of autologous T cells in an HLA-DR and CD47 costimulation-d

68 as reduced compared with cultures containing autologous T cells in the presence of Ag.

69 gG, and IgE Abs when they were cultured with autologous T cells in the presence of IL-4.

70 atient-derived human melanoma cells by their autologous T cells in vitro and potentiates responses to

71 helper T cell 1 (Th1) cytokine expression by autologous T cells in vitro more potently than memory B

72 ors were used as APC to present HIV-1 Ags to autologous T cells in vitro, the strength and specificit

73 nduce a suppressive, regulatory phenotype in autologous T cells in vitro; these patients tended to ha

74 Coculture of adult RSV-infected DCs with autologous T cells induced secretion of gamma interferon

75 sely, coculture of cord RSV-infected DCs and autologous T cells induced secretion of IL-4, IL-6, IL-1

76 IL-10-producing monocytes cocultured with autologous T cells inhibited the proliferation of the T

77 However, an increase in autologous T-cell killing of patient MM cells could not

78 Coculture of DCs with autologous T cells leads to an increase in both the numb

79 ture of mature DCs from X-HIGM patients with autologous T cells led to low IFN-gamma production, wher

80 ia (ALL) we have enrolled for treatment with autologous T cells modified to express 19-28z, a second-

81 The role of autologous T cells needs further delineation but may hel

82 that two distinct proliferative responses of autologous T cells occur in vivo in a lymphopenic settin

83 splantation vaccine and infusion of a primed autologous T-cell product in stimulating specific immuni

84 omly assigned to receive an influenza-primed autologous T-cell product or a nonspecifically primed au

85 The provision of a primed autologous T-cell product significantly improved subsequ

86 Patients who received the influenza-primed autologous T-cell product were significantly more likely

87 s T-cell product or a nonspecifically primed autologous T-cell product.

88 lymphomas were simultaneously infused with 2 autologous T cell products expressing CARs with the same

89 oduced proinflammatory cytokines, stimulated autologous T cell proliferation and IFN-gamma secretion,

90 itic cells to apoptotic non-T cells augments autologous T cell proliferation, and blockade of alpha(v

91 tor population is essential for induction of autologous T cell proliferation, suggesting that cellula

92 non-T cells or dendritic cells to stimulate autologous T cell proliferation.

93 the functional potency of DCs and stimulated autologous T cell proliferation.

94 fect on IL-10 production, for both allo- and autologous T cell proliferation.

95 set that was the most efficient in promoting autologous T cell proliferation.

96 CD25(+) T cells mediate potent inhibition of autologous T cell proliferation.

97 ls is associated with augmented induction of autologous T cell proliferation.

98 gp120-treated mDCs downregulated autologous T-cell proliferation and IFN-gamma production

99 These MDSC-like cells potently suppress autologous T-cell proliferation and IFN-gamma production

100 d P brasiliensis-pulsed mature DCs to induce autologous T-cell proliferation, generation of T helper

101 gulate costimulatory molecules and stimulate autologous T-cell proliferation.

102 nic epitopes in human idiotype recognized by autologous T cells remain largely unknown.

103 se studies demonstrate that EC can stimulate autologous T cell responses to CMV in the absence of acc

104 MDSCs were suppressive of autologous T-cell responses as evidenced by reduced T-ce

105 atocytes, or with HCV core protein, suppress autologous T-cell responses.

106 Most patients with autologous T cells still have profound TD, as defined by

107 Autologous T cells stimulated proliferation of orbital f

108 Autologous T cells stimulated with in vitro-generated, l

109 Immunization with irradiated autologous T cells (T cell vaccination) is shown to indu

110 urfold to sixfold higher using DC-stimulated autologous T cells than with autologous T cells expanded

111 ction of RIbeta cDNAs from SLE subjects into autologous T cells that do not synthesize the RIbeta sub

112 We used autologous T cells that express a CD19-directed CAR (CTL

113 atients had infusions on day 14 after HCT of autologous T cells that had been stimulated using beads

114 psed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retrov

115 and Transwell studies showed suppression of autologous T cells to be contact dependent.

116 rly attenuated the proliferative response of autologous T cells to SEB.

117 with Hd-AdV stimulated the proliferation of autologous T cells to the same level as DCs transduced w

118 We infused autologous T cells transduced with a CD19-directed chime

119 aluate the ability of adoptively transferred autologous T cells transduced with a T-cell receptor (TC

120 L019 cells, a cellular therapy consisting of autologous T cells transduced with an anti-CD19 chimeric

121 Proliferation of allogeneic and autologous T cells was observed when MVA-TRICOM-infected

122 wed that transmission of HIV-1 from MDDCs to autologous T cells was significantly reduced in the pres

123 Autologous T cells were engineered via an 11-day manufac

124 Graded doses of autologous T cells were infused after CHOP chemotherapy

125 d briskly in response to allogeneic, but not autologous, T cells when mixed with irradiated T cells f

126 33(+) MDSCs inhibited IFN-gamma release from autologous T cells, which was restored upon ROS and iNOS

127 ocytes, generated in vitro by stimulation of autologous T cells with MVA-TRICOM-infected CLL cells, s